|
Immune globulin
drug data and news
Immune globulin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Immune globulin
|
| Brand Names/Synonyms |
Ig alpha-2 chain C region; Flebogamma (Instituto Grifols SA); Gamunex (Talecris Biotherapeutics) |
| Indication |
For treatment of immunodeficiencies, thrombocytopenic purpura, Kawasaki disease, gammablobulinemia, leukemia, bone transplant |
|
Sponsored links
|
|
Description |
Mixture of IgG1 and other antibodies derived from human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. Flebogamma contains the IgG antibody specificities found in the general human population. IgG subclasses are fully represented in the following proportions: IgG1 is 70.3%, IgG2, 24.7%, IgG3, 3.1%, and IgG4, 1.90% |
| Pharmacology |
Used as a replacement therapy in inherited humoral immunodeficiency disorders such as severe combined immunodeficiency syndrome, x-linked agammaglobulinemia, and Wiskott-Aldrich Syndrome. The immune globulins target, bind and kill bacterial cells as well as viral particles. IgG is the monomeric immunoglobulin of which there are four subclasses (IgG1, IgG2, IgG3 and IgG4) in differing abundances (66%, 23%, 7% and 4%). IgAs represent about 15% of the immunoglobulins in the blood. These target inhaled or ingested pathogens. |
| Mechanism Of Action |
Antibodies prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage “tagging� or neutralization (via binding) of pathogen toxins. |
Immune globulin News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
SOLUTION |
| Drug_Category |
Immunomodulatory Agents; Anti-infectives; serums (80:04.00) |
| Absorption |
Not Available |
| Interactions |
Not Available |
| Toxicity |
Not Available |
| Organisms Affected |
Not Available |
| Chemical IUPAC Name |
Human antibodies |
| Chemical Formula |
C6332H9826N1692O1980S42 >IgA2 |
| Molecular Weight |
142682.3 |
| Smiles String |
Not Available |
| Melting Point |
61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000). |
| Water Solubility |
Not Available |
| State |
Transparent, slightly viscous, aqueous liquid |
| LogP/Hphobicity |
-0.331 |
| Isoelectric Point |
8.13 |
| Biotransformation |
Not Available |
| Half Life |
>20 hours (mammalian reticulocytes, in vitro). |
| Protein Binding [%] |
Not Available |
| RxList Link |
RXlist |
|
Sponsored links
|
|
| Drug Reference |
http://www.rxlist.com/cgi/generic2/baygam.htm |
| Drug Type |
Approved Drug |
| Accession No |
BIOD00091 |
| CAS Registry Number |
Not Available |
| KEGG Compound ID |
Not Available |
| PubChem ID |
Not Available |
| PharmGKB ID |
Not Available |
| SwissProt ID |
IGHA2_HUMAN (P01877) |
| GenBank ID |
J00221 |
| Drug ID Number [DIN] |
2230920
|
|
|
